Acute localised exanthematous pustulosis

Author: Dr Emily Ryder, Specialist Registrar, Department of Dermatology, Oxford University Hospitals NHS Trust, Oxford, UK. DermNet New Zealand Editor in Chief: Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy editor: Maria McGivern. May 2017.

What is acute localised exanthematous pustulosis?

Acute localised exanthematous pustulosis (ALEP) is the localised form of acute generalised exanthematous pustulosis (AGEP). It can also be referred to as localised pustular drug eruption or localised toxic pustuloderma. ALEP is a rare form of drug reaction. It may occur a few days after starting a medication and usually resolves within a week of discontinuing the medication that triggered it.

Who gets acute localised exanthematous pustulosis?

ALEP is very rare and has only been reported in a small number of patients. It has been suggested that younger female patients may be more at risk of developing ALEP, but there is currently not enough information available to confirm this.

What causes acute localised exanthematous pustulosis?

ALEP may be triggered by various medications. Antibiotics containing amoxicillin seem to be most commonly associated with ALEP.

What are the clinical features of acute localised exanthematous pustulosis?

ALEP has a sudden onset, presenting as localised clustered white or yellow pustules on the surface of a patch of red swollen (oedematous) skin, usually on the face. The pustules are usually superficial and flaccid and have an appearance similar to a localised area of AGEP.

Patients with ALEP usually describe the rash as feeling tight or uncomfortable but the rash is not usually particularly itchy. Some patients with ALEP report feeling tired or unwell; mild fevers have been reported in a small number of patients.

What are the complications of acute localised exanthematous pustulosis?

ALEP may lead to post-inflammatory pigmentation in the affected area. It is not known whether ALEP may lead to severe adverse reactions to drugs.

How is acute localised exanthematous pustulosis diagnosed?

A dermatologist may make the diagnosis of ALEP by recognising the appearance of the rash and the timeframe of its development in relation to a medication, such as an antibiotic. Usually the patient has taken the same medication previously without an adverse response.

The resolution of the rash within days of discontinuing the trigger medication can help to confirm the diagnosis.

What is the differential diagnosis for acute localised exanthematous pustulosis?

Possible differential diagnoses may include:

What is the treatment for acute localised exanthematous pustulosis?

The removal of the trigger medication usually leads to rapid improvement of the rash. Moisturisers (emollients) may help to sooth the skin but no specific treatment is required.

The skin may heal with residual pigment changes (postinflammatory hyperpigmentation or postinflammatory hypopigmentation) that usually improves after months to years.

Once the ALEP diagnosis is confirmed, the patient should be advised to avoid further use of the trigger medication.

Related information

Email Newsletter

Would you like to receive our dermatology updates by email?


Submit your images

We're seeking high-quality photos of skin diseases.  


Machine diagnosis

Watch DermNet's proposal to create a 'Skin Disease Image Recognition Tool' - winner of the 2017 'Clinicians' Challenge Active Award' by the NZ Ministry of Health and HiNZ.

Subscribe to our mailing list

* indicates required
DermNet NZ Newsletter